Author Archives: Marta Figueiredo PhD

Intellia Seeks to Advance Its Gene-editing Therapy to Human Trials

Intellia Therapeutics is advancing clinical manufacturing activities to support its plans to file regulatory applications for first-in-human clinical trials of NTLA-2002, its experimental gene-editing therapy for hereditary angioedema (HAE). The submissions are anticipated in the second half of the year, and the first trial is expected to evaluate…